Cosmo N.V.
0RGI
Rank in Stocks
#7929
Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals... Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, an injectable composition to allow endoscopists with excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Rifamycin, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers' diarrhoea; and Clascoterone, which is in phase-3 clinical trial for the treatment of male pattern hair loss. It is also developing novel UC treatment, which is in phase-2 clinical trial for the treatment of distal inflammatory bowel disease/distal ulcerative colitis/proctitis; BAD Treatment (CB-01-33), which is in phase-2 clinical trial for the treatment of colesevelam formulation/bile acid diarrhea; and CB-03-10, which is in phase-1 clinical trial for the treatment of oncology solid tumors, as well as provides Cosmo's AI technology, a GI Genius intelligent endoscopy system. The company was formerly known as Cosmo Pharmaceuticals N.V. and changed its name to Cosmo N.V. in April 2026. The company was founded in 1997 and is headquartered in Dublin, Ireland.
Share Price
$69.90
Last synced: 2026-11-10
Market Cap
$1.19B
Change (1 day)
-2.55%
Change (1 year)
-14.28%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Cosmo N.V. (0RGI)
Category
Healthcare
EPS for Cosmo N.V. (0RGI)
EPS as of June 2026 TTM: $-0.42
According to Cosmo N.V.'s latest financial reports, its current EPS (TTM) is $-0.42. At the end of 2025 the company had an EPS of $-0.27, a decrease compared to its 2024 EPS of $8.45.
EPS history for Cosmo N.V. from 2004 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.42 | 56.96% |
| 2025 | $-0.27 | -103.19% |
| 2024 | $8.45 | -2,565.54% |
| 2023 | $-0.34 | -130.43% |
| 2022 | $1.13 | -22.62% |
| 2021 | $1.46 | -317.30% |
| 2020 | $-0.67 | -64.25% |
| 2019 | $-1.87 | 35.87% |
| 2018 | $-1.38 | -47.52% |
| 2017 | $-2.63 | -282.30% |
| 2016 | $1.44 | -92.30% |
| 2015 | $18.71 | 207.41% |
| 2014 | $6.09 | -7.80% |
| 2013 | $6.60 | 196.09% |
| 2012 | $2.23 | 224.92% |
| 2011 | $0.69 | 105.30% |
| 2010 | $0.33 | -22.32% |
| 2009 | $0.43 | -54.61% |
| 2008 | $0.95 | 7,362.20% |
| 2007 | $0.01 | -161.35% |
| 2006 | $-0.02 | -105.31% |
| 2005 | $0.39 | -129.95% |
| 2004 | $-1.30 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $1.69 | -498.77% |
US
|
|
| $1.93 | -555.59% |
SE
|
|
| $6.91 | -1,731.43% |
FR
|
|
| $0.02 | -104.60% |
HK
|
|
| $2.71 | -739.41% |
IT
|
Questions about Cosmo N.V.'s earnings per share (EPS)
What is Cosmo N.V.'s earnings per share (EPS)?
Cosmo N.V.'s earnings per share (EPS) over the last twelve months is $-0.42, as of Jun 2026.
What was Cosmo N.V.'s earnings per share (EPS) in 2025?
In 2025, Cosmo N.V.'s earnings per share (EPS) was $-0.27, compared with $8.45 in 2024.
How has Cosmo N.V.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Cosmo N.V.'s earnings per share (EPS) was highest in 2024 ($8.45) and lowest in 2020 ($-0.67).
How does Cosmo N.V.'s earnings per share (EPS) compare with similar companies?
Cosmo N.V.'s earnings per share (EPS) ($-0.42) is lower than that of all 5 similar companies listed above. The highest among them is Ipsen S.A., with $6.91.